This is a routine scientific presentation with no new data or material financial information. Monitor for any future Phase IIa data readouts or IND submission updates, which would be more significant catalysts. The $2M market cap and pre-revenue status mean binary clinical events drive the stock, not conference presentations.
Price Chart
Executive Summary
Oragenics filed an 8-K announcing its Chief Medical Officer will present at the IPAC-RS 2026 Nasal Innovation Forum, highlighting the development of its lead candidate ONP-002 for concussion treatment. The presentation covers the Phase IIa trial design, intranasal delivery platform, and the anticipated Q4 2026 IND submission. This is a routine scientific conference presentation with no new clinical data or financial disclosures.
Key Facts
- CMO James P. Kelly to present at IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026
- Presentation covers ONP-002, a first-in-class intranasal neurosteroid for concussion (mTBI)
- Phase IIa feasibility trial currently enrolling at three sites in Australia
- IND submission anticipated in Q4 2026
- No FDA-approved pharmacological treatments currently exist for mTBI
Financial Impact
No financial data or material financial impact disclosed in the filing
Risk Factors
- No new clinical data disclosed; presentation is forward-looking and non-material
- Company has a $2M market cap with no revenue and significant cash runway risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-042843 |
| Exhibit: ex99-2.htm | 0001493152-26-042843 |
| Document: 0001493152-26-042843-index-headers.html | 0001493152-26-042843 |
| Document: 0001493152-26-042843-index.html | 0001493152-26-042843 |
| Document: 0001493152-26-042843.txt | 0001493152-26-042843 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 5w ago | 8-K | $0.5000 $0.4469 | ▼ −10.62% | ▼ −13.80% | $0.4000 (−20.00%) |
Aug 28, 2026 8w ago | 8-K | $0.5098 $0.4800 | ▲ +5.85% | ▲ +5.66% | $0.4000 (+21.54%) |
May 20, 2026 22w ago | DEFA14A | $0.5900 $0.5882 | ▼ −0.31% | ▼ −0.64% | $0.4000 (−32.20%) |
May 19, 2026 22w ago | 8-K | $0.5700 $0.6100 | ▲ +7.02% | ▲ +6.03% | $0.4000 (−29.82%) |
May 7, 2026 24w ago | 8-K | $0.6100 $0.6100 | · 0.00% | ▼ −3.14% | $0.4000 (−34.43%) |
Apr 13, 2026 28w ago | 8-K | $0.6800 $0.5600 | ▼ −17.65% | ▼ −25.38% | $0.4000 (−41.18%) |
Mar 25, 2026 30w ago | Press Release | $0.5800 $0.6400 | ▼ −10.34% | ▲ +0.32% | $0.4000 (+31.03%) |
Mar 23, 2026 31w ago | EFFECT | $0.6800 $0.6600 | ▼ −2.94% | ▼ −10.36% | $0.4000 (−41.18%) |
Mar 11, 2026 32w ago | 8-K | $0.9600 $0.6000 | ▼ −37.50% | ▼ −39.48% | $0.4000 (−58.33%) |
Mar 11, 2026 32w ago | Press Release | $0.8800 $0.6200 | ▼ −29.55% | ▼ −30.07% | $0.4000 (−54.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers